middlep1

Recent Posts

Europe's stellar decade of prostate cancer innovation

24th September 2011
If, in 2001, you had hormone resistant metastatic prostate cancer, then your treatment options were severely limited. Nothing could extend your life and the focus was on providing you with...
Learn More

Are we all biotech now?

24th June 2011
The past 25 years has witnessed an unparalleled consolidation of the pharmaceutical industry, and some predict a fate similar to the agchem industry where currently six companies control some 75% of...
Learn More

China: Opportunities for biotech firms

24th March 2011
China is serious about medicine. Universal access to basic healthcare, an improving IP environment, Chinese companies desire for innovation and substantial funding opportunities are opening up...
Learn More

Re-Profiling: a Hidden Threat to Originators?

25th February 2011
As James Black is famously quoted as saying, "the most fruitful basis for the discovery of a new drug is to start with an old drug". This has stimulated a heightened search for new indications for...
Learn More

Mitigating Out-sourcing Risk

29th December 2010
Many firms that outsource major projects can end up managing relationships at arms-length. For complex, business-critical projects, this is a high risk strategy as it may fail to give sufficient...
Learn More

Deal Watch: a Review of Notable Deals

29th October 2010
Sharon Finch, Alacrita Advisory Board Member, has published a review of notable deals.
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.